Havens P L, Wendelberger K J, Hoffman G M, Lee M B, Chusid M J
Department of Pediatrics, Medical College of Wisconsin, Milwaukee.
Am J Dis Child. 1989 Sep;143(9):1051-5. doi: 10.1001/archpedi.1989.02150210085023.
A meta-analysis of all nine available controlled trials of corticosteroids for adjunctive therapy for bacterial meningitis was performed. Risks of various outcomes were assessed for control and treatment groups from each study, and risk differences were determined. For each outcome a weighted average of the individual risk differences was calculated. The results show that corticosteroid administration did not reduce the risk of death or neurologic abnormality at hospital discharge or follow-up examination. Based on statistically combined results of the three most recent trials, there is evidence that dexamethasone reduces the risk of bilateral moderate or more severe hearing loss (risk difference, -9%; 95% confidence limits, -15% and -3%). However, this may be true only for children with meningitis caused by Haemophilus influenzae type b. There are inadequate data in adults or in children with meningitis due to other organisms to demonstrate the benefit of dexamethasone administration. Further study is necessary to fully assess the benefits and risks of corticosteroids for adjunctive therapy for bacterial meningitis.
我们对九项现有的关于皮质类固醇用于细菌性脑膜炎辅助治疗的对照试验进行了荟萃分析。评估了每项研究中对照组和治疗组各种结果的风险,并确定了风险差异。对于每个结果,计算了个体风险差异的加权平均值。结果表明,在出院时或随访检查时,使用皮质类固醇并未降低死亡风险或神经功能异常的风险。基于最近三项试验的统计学综合结果,有证据表明地塞米松可降低双侧中度或更严重听力损失的风险(风险差异为-9%;95%置信区间为-15%和-3%)。然而,这可能仅适用于由b型流感嗜血杆菌引起的脑膜炎患儿。在成人或由其他病原体引起脑膜炎的儿童中,尚无足够数据证明使用地塞米松的益处。有必要进行进一步研究,以全面评估皮质类固醇用于细菌性脑膜炎辅助治疗的益处和风险。